Last reviewed · How we verify
exenatide twice daily
At a glance
| Generic name | exenatide twice daily |
|---|---|
| Also known as | Byetta, BYETTA, short-acting glucagon-like peptide-1 receptor agonist |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects (PHASE1)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS (PHASE4)
- Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM (PHASE4)
- Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes (NA)
- Impact of Exenatide on Sleep Duration
- Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |